Literature DB >> 28292435

Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.

Kristin G Anderson1, Ingunn M Stromnes2, Philip D Greenberg3.   

Abstract

T cell dysfunction in solid tumors results from multiple mechanisms. Altered signaling pathways in tumor cells help produce a suppressive tumor microenvironment enriched for inhibitory cells, posing a major obstacle for cancer immunity. Metabolic constraints to cell function and survival shape tumor progression and immune cell function. In the face of persistent antigen, chronic T cell receptor signaling drives T lymphocytes to a functionally exhausted state. Here we discuss how the tumor and its microenvironment influences T cell trafficking and function with a focus on melanoma, and pancreatic and ovarian cancer, and discuss how scientific advances may help overcome these hurdles.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T cell dysfunction; TME; adoptive T cell therapy; genetic engineering; immunotherapy; tumor microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28292435      PMCID: PMC5423788          DOI: 10.1016/j.ccell.2017.02.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  200 in total

1.  Regulation of interleukin-8 expression by cellular pH in human pancreatic adenocarcinoma cells.

Authors:  Q Shi; X Le; B Wang; Q Xiong; J L Abbruzzese; K Xie
Journal:  J Interferon Cytokine Res       Date:  2000-11       Impact factor: 2.607

2.  Systemic and local immunosuppression in pancreatic cancer patients.

Authors:  W von Bernstorff; M Voss; S Freichel; A Schmid; I Vogel; C Jöhnk; D Henne-Bruns; B Kremer; H Kalthoff
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

3.  Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic.

Authors:  Q Shi; J L Abbruzzese; S Huang; I J Fidler; Q Xiong; K Xie
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

4.  Fas and Fas ligand expression in pancreatic adenocarcinoma.

Authors:  Nat L Pernick; Fazlul H Sarkar; Pam Tabaczka; Glenn Kotcher; John Frank; N Volkan Adsay
Journal:  Pancreas       Date:  2002-10       Impact factor: 3.327

5.  Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.

Authors:  E John Wherry; Joseph N Blattman; Kaja Murali-Krishna; Robbert van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Pancreatic tumors show high levels of hypoxia.

Authors:  A C Koong; V K Mehta; Q T Le; G A Fisher; D J Terris; J M Brown; A J Bastidas; M Vierra
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-11-01       Impact factor: 7.038

7.  Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells.

Authors:  L Xu; I J Fidler
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

8.  Fatty acid synthase expression in melanoma.

Authors:  D Innocenzi; P L Alò; A Balzani; V Sebastiani; V Silipo; G La Torre; G Ricciardi; C Bosman; S Calvieri
Journal:  J Cutan Pathol       Date:  2003-01       Impact factor: 1.587

9.  Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.

Authors:  Wolfram V Bernstorff; Jonathan N Glickman; Robert D Odze; Francis A Farraye; Hong G Joo; Peter S Goedegebuure; Timothy J Eberlein
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

10.  Selective delivery of augmented IL-2 receptor signals to responding CD8+ T cells increases the size of the acute antiviral response and of the resulting memory T cell pool.

Authors:  Laurence E Cheng; Philip D Greenberg
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

View more
  189 in total

1.  Chemically Programmable and Switchable CAR-T Therapy.

Authors:  Junpeng Qi; Kohei Tsuji; David Hymel; Terrence R Burke; Michael Hudecek; Christoph Rader; Haiyong Peng
Journal:  Angew Chem Int Ed Engl       Date:  2020-05-18       Impact factor: 15.336

2.  Identifying prostate cancer and its clinical risk in asymptomatic men using machine learning of high dimensional peripheral blood flow cytometric natural killer cell subset phenotyping data.

Authors:  Simon P Hood; Georgina Cosma; A Graham Pockley; Gemma A Foulds; Catherine Johnson; Stephen Reeder; Stéphanie E McArdle; Masood A Khan
Journal:  Elife       Date:  2020-07-28       Impact factor: 8.140

Review 3.  Transcriptional programming of tissue-resident memory CD8+ T cells.

Authors:  J Justin Milner; Ananda W Goldrath
Journal:  Curr Opin Immunol       Date:  2018-04-02       Impact factor: 7.486

Review 4.  The Tumor Metabolic Microenvironment: Lessons from Lactate.

Authors:  Juan C García-Cañaveras; Li Chen; Joshua D Rabinowitz
Journal:  Cancer Res       Date:  2019-06-06       Impact factor: 12.701

5.  The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.

Authors:  Wenjuan Dong; Xiaojin Wu; Shoubao Ma; Yufeng Wang; Ansel P Nalin; Zheng Zhu; Jianying Zhang; Don M Benson; Kai He; Michael A Caligiuri; Jianhua Yu
Journal:  Cancer Discov       Date:  2019-07-24       Impact factor: 39.397

6.  Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors.

Authors:  Tina C Albershardt; Jardin Leleux; Andrea J Parsons; Jordan E Krull; Peter Berglund; Jan Ter Meulen
Journal:  NPJ Vaccines       Date:  2020-06-16       Impact factor: 7.344

Review 7.  Tools to define the melanoma-associated immunopeptidome.

Authors:  Eva Bräunlein; Angela M Krackhardt
Journal:  Immunology       Date:  2017-08-28       Impact factor: 7.397

8.  Interleukin-23 engineering improves CAR T cell function in solid tumors.

Authors:  Xingcong Ma; Yang Xu; Peishun Shou; Christof Smith; Yuhui Chen; Hongwei Du; Chuang Sun; Nancy Porterfield Kren; Daniel Michaud; Sarah Ahn; Benjamin Vincent; Barbara Savoldo; Yuliya Pylayeva-Gupta; Shuqun Zhang; Gianpietro Dotti
Journal:  Nat Biotechnol       Date:  2020-02-03       Impact factor: 54.908

9.  EZH2 inhibition: a promising strategy to prevent cancer immune editing.

Authors:  Ning Kang; Mark Eccleston; Pier-Luc Clermont; Maryam Latarani; David Kingsley Male; Yuzhuo Wang; Francesco Crea
Journal:  Epigenomics       Date:  2020-09-17       Impact factor: 4.778

Review 10.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.